Association between Thigh Muscle Volume and Leg Muscle Power in Older Women

Ulrich Lindemann1*, Christian Mohr1*, Juergen Machann2,3†, Konstantinos Blatzonis4‡, Kilian Rapp1†, Clemens Becker1*

1 Department of Clinical Gerontology and Rehabilitation, Robert-Bosch-Hospital, Stuttgart, Germany, 2 Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany, 3 Department of Diagnostic and Interventional Radiology, Section on Experimental Radiology, University Hospital Tübingen, Tübingen, Germany, 4 Department of Radiology and Nuclear Medicine, Robert-Bosch-Hospital, Stuttgart, Germany

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* ulrich.lindemann@rbk.de

Abstract

The construct of sarcopenia is still discussed with regard to best appropriate measures of muscle volume and muscle function. The aim of this post-hoc analysis of a cross-sectional experimental study was to investigate and describe the hierarchy of the association between thigh muscle volume and measurements of functional performance in older women. Thigh muscle volume of 68 independently living older women (mean age 77.6 years) was measured via magnetic resonance imaging. Isometric strength was assessed for leg extension in a movement laboratory in sitting position with the knee flexed at 90° and for hand grip. Maximum and habitual gait speed was measured on an electronic walk way. Leg muscle power was measured during single leg push and during sit-to-stand performance. Thigh muscle volume was associated with sit-to-stand performance power (r = 0.628), leg push power (r = 0.550), isometric quadriceps strength (r = 0.442), hand grip strength (r = 0.367), fast gait speed (r = 0.291), habitual gait speed (r = 0.256), body mass index (r = 0.411) and age (r = -0.392). Muscle power showed the highest association with thigh muscle volume in healthy older women. Sit-to-stand performance power showed an even higher association with thigh muscle volume compared to single leg push power.

Introduction

The loss of muscle function and mass in the ageing population is increasingly recognized as relevant, common and modifiable. Depending on the definition, the prevalence of sarcopenia in older persons 60–80 years old is often reported in the range of 5–13% [1]. Sarcopenia is increasing to more than 30% in persons 80 years old and older [2]. Many common medical conditions such as stroke, hip fracture and diabetes mellitus and medications like corticosteroids or α-blockers increase the incidence of sarcopenia [3–5]. Public bodies and authorities
such as the World Health Organisation, the United States National Institute of Health, the European Medicines Agency and the United States Food and Drug Administration are currently discussing different definitions for sarcopenia. One major point is the question whether sarcopenia should be recognized as a disease entity in the revised International Classification of Diseases and Related Health Problems or as a syndrome. An even bigger challenge is the definition of sarcopenia. A European formalized consensus group has made an attempt to come up with a clinical definition for screening [6]. A key issue of a definition is the relationship between muscle mass, impairment and function. There are considerable disparities in studies how and where to measure muscle mass, muscular impairment and functional loss caused by sarcopenia. Many studies have pragmatically measured total body muscle mass using dual-energy X-ray absorptiometry (DXA) with limited accuracy. At the same time muscle function was measured looking at lower extremity function such as habitual gait speed or sometimes hand grip strength as a surrogate marker. The pharmaceutical industry has started trials for the development and evaluation of new medications [7] and non-pharmaceutical interventions [8,9]. In summary, effective treatments to prevent, slow and/or reverse the progression of sarcopenia could be very relevant to influence ageing trajectories. However, in order to assess incidence, prevalence and treatment effects accurate measures are required to measure, screen, assess and follow older persons and certain patient groups. This requires methods to quantify muscle mass and relevant functional measures.

The current gold standard to measure muscle mass is magnetic resonance imaging (MRI) [10]. For muscle mass screening and other purposes other methods such as DXA or bioelectrical impedance analysis (BIA) may be required but their limitations must be realized. To measure muscle strength, power and functional loss caused by sarcopenia several methods have been established and are widely accepted but often not rigorously applied. There is consensus that muscle strength parameters, such as hand grip strength and isometric measurements of the lower extremity, should be measured. Functional performance tests, such as the assessment of chair rise time and gait speed are required and accepted to study the effects of sarcopenia on the loss of independence. All of these tests have been instrumented to increase their accuracy and objectivity [11,12]. Although leg muscle power has been identified as an important determinant of mobility skills in older adults [13] and although leg muscle power has been shown to be associated with muscle volume in young persons [14], at present this measure is often not used to show the efficacy of strategies to counteract sarcopenia. The standard equipment to measure muscle power is the Nottingham Power Rig, where power is calculated from a single leg push in a seated position (Bassey & Short, 1990). Recently it has been shown that the sit-to-stand (STS) power performance, as a functional measure of the lower extremity, can objectively be assessed in older persons by a linear encoder [15,16] or by body-worn sensors [17]. The measurement of muscle power is often neglected even though the relevance is obvious [13,18,19]. The association between muscle mass, strength, function and power is still understudied. Often, authors implicitly state that these measures can be used as surrogate markers interchangingly. While this might be justified for epidemiological studies or sometimes in clinical practise it is certainly questionable in efficacy studies on new medications and non-pharmaceutical RCTs.

The aim of this post-hoc analysis was to investigate and describe the hierarchy of the association between thigh muscle volume and measurements of functional performance in older women. In particular we were interested in the consensus based use of hand grip strength and habitual gait speed to screen for sarcopenia and to compare these with measures of muscle power. We hypothesized that leg muscle power is a potent measure in this hierarchy.
Methods

Subjects and design

Sixty-eight older women (mean age 77.6 years) were included into this cross-sectional post-hoc analysis. The original study (DRKS00003622) was to compare physical performance in a 15°C and a 25°C temperature indoor environment [20]. Data from the 25°C temperature condition were used for this post-hoc analysis. From the original data set of 93 subjects 25 data sets were excluded, because the pre-defined margins of the thigh muscle volume, which were used for muscle volume analysis via MRI, were not precisely detectable, e.g. because of prostheses. Inclusion criteria of the original study were: age ≥ 70 years, female gender and community dwelling. Women with uncontrolled cardiac illness or a relevant functional impairment due to neurological and/or orthopedic diseases that significantly influenced transfers or walking performance were excluded from the study. Cognitive impairment based on screening via the Short Orientation Memory Concentration Test [21] with a cut-off score >10 (worst score 28) was another exclusion criterion. Comorbidity was described using the Functional Comorbidity Index [22]. The body mass index (BMI) was calculated from body mass and body height and was used as a descriptive parameter and for analysis.

The study was conducted according to the principles expressed in the Declaration of Helsinki. Prior to first assessment all participants gave written informed consent to participate in the study. The study was approved by the ethics committee of the medical faculty of the university of Tuebingen, Germany (578/2011BO2). The individual in this manuscript, shown in a figure, has given written informed consent (as outlined in PLOS consent form) to publish these case details.

Muscle volume imaging

Muscle volumes of both thighs were assessed using MRI (MAGNETOM Aera1.5 T, Siemens Healthcare, Erlangen, Germany). Subjects were lying in supine position on the spine-array coil and were covered by an 8-channel body array-coil of the manufacturer. Imaging was performed from trochanter minor down to the transition of the muscle rectus femoris to its tendon applying an axial T1-weighted fast spin-echo technique. Measurement parameters: TE = 9.8 ms, TR = 567 ms, matrix size 346x512, in-plane resolution 0.8x0.9 mm, acquisition time 3:08 min. with a slice thickness of 8 mm and without interslice gap. A home-built semi-automatic segmentation program based on Matlab (Matlab 8.4, the MathWorks Inc., Natick, Massachusetts, USA) was used for determination of muscle volume. This threshold-based algorithm segments three classes: noise, lean tissue (i.e. muscle) and adipose tissue as exemplary shown in Fig 1. Pixels in the respective class were summed and the cross-section was calculated by multiplying the number of pixels by the in-plane resolution. Summing up all slices resulted in total volume of lean tissue and adipose tissue.

In a second step the left and the right thigh muscles were separated by manually drawing a region of interest covering the left and right thigh muscle cross-section, respectively, in each slide. The total muscle volume resulted in summing up all slides and multiplying by scan thickness. The values [cm³] of both thighs and the sum were used for analysis.

Muscle parameters of functional performance

Muscle strength. Maximum quadriceps strength was assessed using a hand-held dynamometer (microFET2, Biometrics, Almere, The Netherlands) in a sitting position with the knee flexed at 90°. Participants were instructed to stretch their knee as much as possible. After
measuring the lever distance (knee joint—application), the sum of the maximum force momentum [Nm] from a single trial of each leg was used for analysis.

Maximum hand grip strength [kg] was assessed with a dynamometer (Jamar, MSD, Londerzeel, Belgium, respectively). The value of a single trial with the preferred hand was used for analysis.

**Muscle function.** Maximum leg muscle power was assessed using the Nottingham Power Rig [23]. Subjects were seated with the pelvis supported at the back. They were instructed to
push as hard as possible against a plate with a single leg over a distance of 16.5 cm. Power was inferred from the angular velocity and inertia of a flywheel, which was driven by a chain connected to the foot plate by a lever. After two sub-maximal trials of each leg, the maximum results for left and right leg power [W], out of three trials for each leg, were used separately for analysis. Additionally, the maximum results were added and used for analysis.

Participants were asked to stand up from a standard chair (46 cm) with armrests as quickly as possible to the full standing position in order to measure the STS performance. A linear encoder (MuscleLab Powermodel MLPRO, Ergotest Technology, Langesund, Norway) was fixed at the person’s hip near vertebra L5 with a waist belt and measured the velocity of the hip as a function of time (Fig 2). After demonstration of the task and one sub-maximal trial STS performance power [W] was calculated from the hips’ maximum velocity multiplied by body weight [16] and was used for analysis.

Gait speed was assessed over a distance of 8 m with an additional 3 m for acceleration and deceleration [24]. Spatiotemporal gait parameters were recorded on an instrumented walkway with embedded pressure sensors (GAITRite, CIR Systems, Haverton, PA, USA), and calculated by application software. The use of a walking aid was allowed. The instructions were to walk along the walk-way once at ‘normal speed’ and once ‘as fast as possible, but safely’. Habitual and maximum gait speeds [m/s] were used for analysis.

Statistical analysis

The associations between variables were expressed using Pearson’s coefficient of correlation. In addition, a linear regression model was conducted to analyze the independent and combined

![Fig 2. Linear encoder fixed at the person’s hip measuring the velocity of the hip as a function of time.](https://doi.org/10.1371/journal.pone.0157885.g002)
contribution of the possible determinants of thigh muscle volume. Parameters were included, if the association with muscle volume was $r > 0.4$. All analyses were conducted using SPSS Version 16 (IBM Corp., Armonk, USA).

**Results**

The mean age of the women was 77.6 years (SD 4.9 years) and their mean habitual gait speed was 1.1 m/s (SD 0.22 m/s) with 6 women using a walking aid. The cohort is described in more detail in Table 1.

The highest associations between thigh muscle volume and other parameters were found for STS performance power ($r = 0.628$; Fig 3) and for leg push power sum value ($r = 0.550$).

Somewhat lower correlations were observed for isometric quadriceps strength ($r = 0.442$). The association between thigh muscle volume and hand grip strength ($r = 0.367$), fast gait speed ($r = 0.291$) and habitual gait speed ($r = 0.256$) were even lower in this sample.

Total thigh muscle volume was strongly associated with single left and right muscle volume ($r = 0.980$ and $r = 0.979$, respectively). Coefficients of correlation describing the single leg association between thigh muscle volume and leg push power were $r = 0.574$ for left leg and $r = 0.431$ for right leg. The associations between thigh muscle volume and body mass index and age were $r = 0.411$ and $r = -0.392$, respectively. A linear regression model including STS performance power, isometric strength and body mass index as independent variables explained 50% of the variance of thigh muscle volume.

The coefficients of inter-correlation between parameters of functional performance ranged from $r = -0.142$ to $r = 0.608$ and are shown in detail in Table 2.

| Table 1. Descriptive data of all (n = 68) included women. |
|---------------------------------------------------------|
| **Mean (SD)** | **Range** |
| Age [years] | 77.6 (4.99) | 70–89 |
| Height [cm] | 160 (6.26) | 145–173 |
| Body mass [kg] | 68.5 (11.88) | 44–102 |
| BMI [kg/m²] | 26.9 (4.17) | 17–38 |
| Comorbidity (0–18) | 2.7 (1.68) | 0–6 |
| Cognition (0–28) | 2.6 (3.06) | 0–10 |
| Total thigh muscle volume [cm³] | 4021 (684.98) | 2768–5639 |
| Left thigh muscle volume [cm³] | 2068 (351.62) | 1421–2960 |
| Right thigh muscle volume [cm³] | 1953 (347.83) | 1346–2906 |
| Sit-to-stand power [W] | 727 (174.63) | 365–1161 |
| Nottingham Power Rig, both legs [W] | 213 (73.08) | 123–464 |
| Nottingham Power Rig, left leg [W] | 111 (38.61) | 47–232 |
| Nottingham Power Rig, right leg [W] | 102 (36.70) | 48–235 |
| Habitual gait speed [m/s] | 1.10 (0.22) | 0.49–1.54 |
| Maximum gait speed [m/s] | 1.76 (0.34) | 0.73–2.39 |
| Quadriceps strength [Nm] | 126 (33.39) | 56–232 |
| Hand grip strength [kg] | 24.4 (4.12) | 15–33 |

BMI = Body Mass Index; Comorbidity assessed by the Functional Comorbidity Index; Cognition assessed by the Short Orientation Memory Concentration Test; better score values are underlined

doi:10.1371/journal.pone.0157885.t001
Discussion

In this group of relatively healthy older women we found a moderate association between thigh muscle volume and muscle power. These results are corroborated by a study with younger subjects [14]. The highest association between muscle thigh volume and functional performance was found for power measured during the STS transfer.

The low association between thigh muscle volume and hand grip strength as well as habitual gait speed questions the usefulness of these parameters to screen older persons for sarcopenia [19,6]. It seems problematic to use these parameters as surrogate markers for outcome studies,

Table 2. Association between total thigh muscle volume and parameters of functional performance described by Pearson’s coefficient of correlation.

|                          | STS power | Power Rig (sum value) | Gait speed (maximum) | Gait speed (habitual) | Quadriceps strength | Hand grip strength |
|--------------------------|-----------|-----------------------|----------------------|-----------------------|---------------------|-------------------|
| Thigh muscle volume (total) | 0.628     | 0.550                 | 0.291                | 0.256                 | 0.442               | 0.367             |
| Sit-To-Stand power       | 0.608     | 0.507                 | 0.173                | 0.256                 | 0.442               | 0.409             |
| Power Rig (sum value)    |            | 0.500                 | 0.147                | 0.607                 | 0.490               |                   |
| Gait speed (maximum)     |            |                       | 0.319                | 0.370                 | 0.344               |                   |
| Gait speed (habitual)    |            |                       |                      | 0.172                 | -0.142              |                   |
| Quadriceps strength      |            |                       |                      |                       |                     | 0.476             |

doi:10.1371/journal.pone.0157885.t002
such as RCTs with pharmaceutical interventions. This is not questioning the use of gait speed and other parameters as outcome parameters for other purposes.

Most studies currently include standardized measurements for hand grip strength and gait speed. Power measurements are performed less frequently although the relevance has been recognized since many years [13]. The reason for excluding power is mostly related to the cost and space requirements of the equipment. The recommendation to use hand grip strength as a functional outcome measure of sarcopenia was based on similar results for leg power, assessed by the Nottingham Power Rig, and hand grip strength to predict poor walking performance, but better practicability of hand grip strength [19]. In a recent study, stair climbing, chair rise and fast gait speed were affected by a myostatin inhibitor intervention to increase muscle mass [25]. Since all these parameters assess some kind of strength and distance per time, which describes "power", the high association between thigh muscle volume and STS performance power in our study is reasonable. Simple and objective measures of muscle power are available now [15,16] and therefore we included this method. This was found to have the strongest correlation with thigh muscle volume. When measuring muscle power during the STS transfer body weight and height are major factors which is different from the power rig assessment which is performed in a sitting position. Inclusion of body mass index into the regression model to predict muscle volume takes into account the obvious influences of body mass and height. Furthermore and with regard to functional use of legs, punctum fixum and punctum mobile are transposed during assessment of leg push power via Nottingham Power Rig. Our results of higher association between functional assessment of muscle power and thigh muscle volume compared to lower association between sitting leg push power and thigh muscle volume are corroborated by studies of Wilhelm et al. [26]. They found higher association between counter-movement jump power and thigh muscle quality (echo intensity) compared to lower association between leg extensor power and thigh muscle quality.

In our study, the muscle volume was calculated via MRI. In contrast to the use of DXA, we have chosen MRI, which has no radiation exposure. DXA measures the full body muscle volume, whereas our method only assessed the leg muscle volume. This makes it possible to better match the leg power with the muscle volume of the thigh. On the other hand, the hand grip strength is not mapped directly in the muscle volume values. The measurement of muscle volume via MRI and the MATLAB based program allows a detailed analysis of the real muscle volume but is more complex, costly and time consuming than DXA. With regard to detection of sarcopenia it must be questioned which muscle groups are most relevant [27] and whether these muscle groups can be better measured via DXA or via MRI. In previous studies it has been shown that there is an expected correlation between the results of DXA and MRI assessed muscle volume, but that DXA underestimates the muscle volume [28]. With regard to controlled studies to improve muscle volume, small but relevant improvement of muscle volume may not be detected or underestimated by DXA-measurement due to limited accuracy.

The history of the discussion on osteoporosis indicates that key zones for definitions are preferable for the diagnosis and for consented definitions [29,30]. In the case of sarcopenia this means that if lower extremity function, muscle strength and power are used for diagnosis, imaging should be done with an accurate measure in the same region. This is currently not addressed in the ongoing consensus discussions.

A limitation of our study is that the results are valid only for this cohort of healthy older women. Future and preferably prospective studies should evaluate our findings in a larger sample size of frail older persons and should explicitly include men.

In conclusion, power showed the highest association with thigh muscle volume in healthy older women. The power measurement of STS performance showed an even higher association with thigh muscle volume compared to the measurement via Nottingham Power Rig.
This should be discussed in the debate on screening tools and outcome measurements for sarcopenia.

Supporting Information
S1 Raw Data. contains the complete data set.

(XLSX)

Author Contributions
Conceived and designed the experiments: UL CM KR CB. Performed the experiments: UL CM. Analyzed the data: UL CM JM KB. Contributed reagents/materials/analysis tools: UL JM KB. Wrote the paper: UL CM JM KB CR KB. Designed the software used in analysis: JM.

References
1. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014; 5(4): 253–259. doi: 10.1007/s13539-014-0161-y PMID: 25425503
2. Morley JE. Sarcopenia in the elderly. Fam Pract. 2012; 29 Suppl 1: i44–i48. doi: 10.1093/fampra/cmr063 PMID: 22399555
3. Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenburg J, Nilwik R, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc. 2013; 14(8): 585–592. doi: 10.1016/j.jamda.2013.02.006 PMID: 23537893
4. Scherbakov N, von Haehling S, Anker SD, Dirnagl U, Doehner W. Stroke induced Sarcopenia: muscle wasting and disability after stroke. Int J Cardiol. 2013; 170(2): 89–94. doi: 10.1016/j.ijcard.2013.10.031 PMID: 24231058
5. Villani AM, Miller MD, Cameron ID, Kurrle S, Whitehead C, Crotty M. Development and relative validity of a new field instrument for detection of geriatric cachexia: preliminary analysis in hip fracture patients. J Cachexia Sarcopenia Muscle. 2013; 4(3): 209–216. doi: 10.1007/s13539-013-0108-8 PMID: 23686412
6. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–423. doi: 10.1159/000356740 PMID: 22457615
7. White TA, LeBrasseur NK. Myostatin and sarcopenia: opportunities and challenges—a mini-review. Gerontology. 2014; 60(4): 289–293. doi: 10.1159/000356740 PMID: 22457615
8. Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2015; 6(3): 197–207. doi: 10.1002/jcsm.12043 PMID: 26401465
9. Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014; 43(6): 748–759. doi: 10.1093/ageing/afu115 PMID: 25241753
10. Delmonico MJ, Kostek MC, Johns J, Hurley BF, Conway JM. Can dual energy X-ray absorptiometry provide a valid assessment of changes in thigh muscle mass with strength training in older adults? Eur J Clin Nutr. 2008; 62(12): 1372–1378. PMID: 17684523
11. Cutlip RG, Mancinelli C, Huber F, DiPasquale J. Evaluation of an instrumented walkway for measurement of the kinematic parameters of gait. Gait Posture. 2000; 12: 134–138. PMID: 10998610
12. Zhang W, Regterschot GRH, Schaaova H, Badus H, Zijlstra W. Test-retest reliability of a pendant-worn sensor device in measuring chair rise performance in older persons. Sensors. 2014; 14(5): 8705–8717. doi: 10.3390/s140508705 PMID: 24841248
13. Bean JF, Leveille SG, Kiely DK, Bandinelli S, Guralnik JM, Ferrucci L. A comparison of leg power and leg strength within the InCHIANTI study: which influences mobility more? J Gerontol A Med Sci. 2003; 58: 726–733.
14. O’Brien TD, Reeves ND, Baltzopoulos V, Jones DA, Maganaris CN. Strong relationships exist between muscle volume, joint power and whole-body external mechanical power in adults and children. Exp Physiol. 2009; 94(6): 731–736. doi: 10.1113/expphysiol.2008.045062 PMID: 19251963
15. Gray M, Paulson S. Developing a measure of muscular power during a functional task for older adults. BMC Geriatr. 2014; 14: 145. doi: 10.1186/1471-2318-14-145 PMID: 25551186

16. Lindemann U, Farahmand P, Klenk J, Blatzonis K, Becker C. Validity of linear encoder measurement of sit-to-stand performance power in older people. Physiotherapy. 2015; 101(3): 298–302. doi: 10.1016/j.physio.2014.12.005 PMID: 25796540

17. Zijlstra W, Bissellin RG, Schumbohm S, Baldus H. A body-fixed-sensor-based analysis of power during sit-to-stand movements. Gait Posture. 2010; 31: 272–278. doi:10.1016/j.gaitpost.2009.11.003 PMID: 19963386

18. Harridge S, Young A. Strength and Power. In: Evans J, Williams T, Beattie B, Michel JP, Wilcock CK, editors. Oxford Textbook of Geriatric Medicine. Langton, Oxford; 2000.

19. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi AM, Rantanen T, Guralnik JM, Ferrucci L. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol. 2003; 95(5): 1851–1860. PMID: 14555665

20. Lindemann U, Oksa J, Skelton DA, Beyer N, Klenk J, Zscheile J, et al. Effect of cold indoor environment on physical performance of older women living in the community. Age Ageing. 2014; 43(4): 571–575. doi: 10.1093/ageing/afu057 PMID: 24855113

21. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983; 140: 734–739. PMID: 6846631

22. Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol. 2005; 58: 595–602. PMID: 15878473

23. Bassey EJ, Short AH. A new method for measuring power output in a single leg extension: feasibility, reliability and validity. Eur J Appl Physiol Occup Physiol. 1990; 60:385–390. PMID: 2369911

24. Lindemann U, Najafi B, Zijlstra W, Hauer K, Muche R, Becker C, et al. Distance to achieve steady state walking speed in frail elderly persons. Gait Posture. 2008; 27: 91–96. PMID: 17383185

25. Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015; 3(12): 948–957.

26. Wilhelm EN, Rech A, Minozzo F, Radaelli R, Botton CE, Pinto RS. Relationship between quadriceps femoris echo intensity, muscle power, and functional capacity of older men. Age. 2014; 36(3): 9625. doi: 10.1007/s11357-014-9625-4 PMID: 24515898

27. Cawthon PM. Assessment of Lean Mass and Physical Performance in Sarcopenia. J Clin Densitom. 2015; 18(4): 467–471. doi: 10.1016/j.jcld.2015.05.063 PMID: 26071168

28. Maden-Wilkinson TM, Degens H, Jones DA, McPhee JS. Comparison of MRI and DXA to measure muscle size and age-related atrophy in thigh muscles. J Musculoskelet Neuronal Interact. 2013; 13(3): 320–328. PMID: 23989253

29. Bernabei R, Martone AM, Ortolani E, Landi F, Marzetti E. Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab. 2014; 11(3): 201–207. PMID: 25568654

30. Nayak S, Edwards DL, Saleh AA, Greenspan SL. Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int. 2015; 26(5): 1543–1554. doi: 10.1007/s00198-015-3025-1 PMID: 25844147